Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants
Vaccines pave the way out of the SARS-CoV-2 pandemic. We have developed a virus-like particle (VLP)-based vaccine using the baculovirus-insect cell expression system, a robust production platform known for its scalability, low cost, and safety. Baculoviruses were constructed encoding SARS-CoV-2 spike proteins: full-length S, stabilized secreted S, or the S1 domain. This two-component nanoparticle vaccine can now be further developed to help alleviate the burden of COVID-19.
2018 ◽
Vol 60
(11)
◽
pp. 820-832
◽
1994 ◽
Vol 267
(5)
◽
pp. C1501-C1505
◽
2019 ◽
pp. 179-189
2015 ◽
Vol 35
(6)
◽
pp. 1715-1719
◽
1994 ◽
Vol 49
(24)
◽
pp. 4133-4141
◽
2018 ◽
Vol 71
(3)
◽
pp. 185-192
◽